Imsidolimab

• Description :

  Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases[1][2].

• Product Name Alternative :

  ANB 019

• UNSPSC :

  12352203

• Target :

  Interleukin Related

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/imsidolimab.html

• Purity :

  98.63

• Solubility :

  10 mM in DMSO

• Smiles :

  [Imsidolimab]

• Molecular Weight :

  (146.6 kDa)

• References & Citations :

  [1]Gudjonsson J E, et al. 34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study[J]. Journal of the American Academy of Dermatology, 2022, 87 (3) : AB70.|[2]Iznardo H, et al. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021 Apr 21;22 (9) :4344.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [2102543-86-0]